Search Results

Ginkgo Bioworks announced the acquisition of StrideBio’s adeno-associated virus capsid discovery and engineering platform assets with a secondary close scheduled upon the transfer of certain additional in-license agreements to Ginkgo.

StrideBio, Inc. today announced the appointment of industry veteran Mark Velleca, M.D., Ph.D. as Chief Executive Officer and a member of its Board of Directors.

Newly created roles will support StrideBio’s operations across strategy, regulatory affairs, quality, and patient advocacy.

StrideBio, Inc today announced the achievement of several significant operational milestones.

StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Deborah D. Ascheim, M.D., to the newly created position of Chief Medical Officer.

StrideBio receives exclusive license to novel cross-species evolved AAV vectors and an enzymatic approach for neutralizing antibody evasion

StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith as Chief Operating Officer. In this key position, Mr. Monteith will play a lead role in expanding the scale and breadth of StrideBio’s operations, incl

StrideBio, Exicure and Syndax Pharmaceuticals tapped new CEOs.

- Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs - - Financing will also support organizational growth and GMP manufacturing expansion, building on the company’s current 1000 liter scale in-house production process -

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the signing of a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system (CNS) and neuromuscular targets.